论文部分内容阅读
目的:探讨急性移植物抗宿主病(aGVHD)患者miR-155的表达水平及其临床意义。方法:采用造血干细胞移植患者移植第0、第7、第14、第21及第28天的血浆标本,实时荧光定量PCR(qPCR)方法检测miR-155相对表达量,酶联免疫吸附试验(ELISA)法检测患者血浆中白细胞介素(IL)-4、IL-7、IL-10的含量。结果:miR-155在移植后第7天开始逐渐升高,到第28天时升高明显,患者移植后不同时间点miR-155相对表达量比较差异具有统计学意义(P<0.05)。allo-HSCT后不同时间点IL-4、IL-7、IL-10水平比较,差异均无统计学意义(P>0.05)。结论:allo-HSCT后miR-155较IL-4、IL-7、IL-10水平变化出现早,可作为早期诊断和预测a GVHD的无创性生物标记物。
Objective: To investigate the expression of miR-155 in patients with acute graft versus host disease (aGVHD) and its clinical significance. Methods: Plasma samples were collected from 0, 7, 14, 21 and 28 days after hematopoietic stem cell transplantation. The relative expression of miR-155 was detected by real-time quantitative PCR (qPCR) ) Method was used to detect the levels of interleukin (IL) -4, IL-7 and IL-10 in the plasma of patients. Results: miR-155 gradually increased from the 7th day after transplantation and increased significantly on the 28th day. The relative expression of miR-155 at different time points after transplantation was statistically significant (P <0.05). The levels of IL-4, IL-7 and IL-10 at different time points after allo-HSCT showed no significant difference (P> 0.05). Conclusion: Allo-HSCT miR-155 levels earlier than IL-4, IL-7, IL-10 levels, which can be used as a noninvasive biomarker for early diagnosis and prediction of a GVHD.